Lyndsay Shipp, MD
Dermatology · Oxford, MSNPI 1063724987
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $196,632 of the $246,345 with a category attached, or 79.8%. Mallinckrodt Hospital Products Inc. accounts for 61.3% of it on its own, with 27 other manufacturers making up the rest. 2025 is the largest year on record at $142,443, more than ten times the $10,505 reported in 2019. Among dermatology clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,028 payments — averaging $239.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$151K
- Amgen$40K
- Pfizer$29K
- Bristol Myers Squibb$9K
- AbbVie$6K
- Sun Pharmaceutical Industries Inc.$2K
- plus $9K from 22 others
What the payments were for
- Consulting fees$7,3383%
- Speaking & faculty fees$196,63280%
- Travel & lodging$22,8999%
- Food & beverage$18,9968%
- Education$4810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 110 | $151,060 |
| Amgen | 77 | $39,973 |
| Pfizer | 86 | $29,426 |
| Bristol Myers Squibb | 21 | $9,396 |
| AbbVie(2 entities) | 238 | $6,417 |
| Sun Pharmaceutical Industries Inc. | 70 | $1,505 |
| Johnson & Johnson | 59 | $1,171 |
| Revance Therapeutics, Inc. | 14 | $952 |
| UCB, Inc. | 58 | $931 |
| Novartis | 67 | $810 |
| LEO Pharma Inc. | 41 | $704 |
| Regeneron Healthcare Solutions, Inc. | 33 | $631 |
| Sanofi | 26 | $611 |
| Galderma Laboratories, L.p. | 21 | $500 |
| Lilly USA, LLC | 22 | $462 |
| E.r. Squibb & Sons, L.L.C. | 22 | $368 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 12 | $294 |
| Incyte Corporation | 13 | $290 |
| Merz North America, Inc. | 1 | $175 |
| Dermira, Inc. | 6 | $107 |
| Boehringer Ingelheim | 4 | $103 |
| Organon | 8 | $102 |
| Janssen Scientific Affairs, LLC | 1 | $85 |
| Arcutis Biotherapeutics, Inc. | 4 | $74 |
| Dermavant Sciences, Inc. | 5 | $73 |
| Strata Skin Sciences, Inc. | 5 | $53 |
| Biofrontera Inc. | 2 | $38 |
| Helsinn Therapeutics (U.S.), Inc. | 2 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$246,345 in reported general payments places this provider in the 95th percentile of 78 dermatology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 11 | $149,252 |
| RinvoqUpadacitinib | 15 | $91,079 |
| Dupixent PenDupilumab | 19 | $69,159 |
| Imiquimod | 142 | $3,169 |
| Metronidazole | 29 | $2,203 |
| Clobetasol Propionate | 37 | $1,708 |
| Betamethasone Dipropionate | 33 | $1,695 |
| CiclopiroxCiclopirox Olamine | 25 | $1,336 |
| Triamcinolone Acetonide | 92 | $1,079 |
| Ketoconazole | 66 | $799 |
| Clindamycin Phosphate | 22 | $717 |
| Doxycycline Hyclate | 38 | $656 |
| Hydroxychloroquine Sulfate | 17 | $446 |
| Mupirocin | 55 | $389 |
| Minocycline Hcl | 25 | $360 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $6,417 | $91,07915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 78 dermatology providers in Mississippi.
Other dermatology in Oxford
- Philip LoriaOxford$9K
- Jenna CooperOxford$6K
- Jeremy JacksonJackson$450K
- Lindsey ZubritskyOcean Springs$349K
- Maureen OffiahHattiesburg$275K
- Steven ShapiroHattiesburg$165K
- Joseph TerracinaGreenville$86K
- Thy HuynhJackson$51K
- Patrick BolerClinton$44K
- Jeffrey HouinTupelo$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.